TACR1 and cancer: Given the role of SP/NK-1R in different molecular pathways related to resistance, and even though there is still a need to improve the current knowledge of mechanisms of SP/NK-1R antagonists, such as aprepitant, on resistant cancer cells, studies aimed to evaluate the potential utility of these drugs, either as mono- or as part of drug combination therapies, for the treatment of resistant tumors are justified.